Taken together, these findings underscore the importance of an in-depth understanding of the biology and pharmacology of specific subtypes of 5-HT receptors and how this may lead to the development of novel treatments with selective clinical efficacies and fewer side effects compared with prior medications.
A tip of the hat to Sean Hall for bringing this to light
The approval of lorcaserin by the FDA in June 2012 marks the culmination of many years of basic science investigation in fields as disparate as the central control of appetite and drug-induced valvular
heart disease. Thus, the pivotal discoveries that 5-HT2C receptors are essential mediators of both appetite and the anorectic actions of fenfluramine and that the closely related receptor 5-HT2B is responsible for drug-induced valvular heart disease paved the way for the design of novel serotonergic drugs predicted to be effective in reducing appetite without cardiovascular side effects. Additionally, since it is now well established that drugs can selectively engage either G protein or β-arrestin signaling drugs with selective signaling bias for one pathway over another may have distinct clinical advantages over drugs without functional selectivity. It will be important to determine whether 5-HT2C agonists with signaling bias represent a therapeutic advance over drugs without functional selectivity.
Thanks aahmad. This is important study - says fat still carries health risks even when cholesterol, blood pressure, and sugar levels are normal. No such thing as 'healthy overweight'. Looked at data for 60,000 people. Published in Annals of Internal Medicine.
We need to establish a network of Muslim countries and organize symposium on Ramadan and Health after every two years. There is also a need to have a separate chapter on fasting in our medical text books. This was stated by Dr. Mohsen Nematy from Mashad University of Medical Sciences, Iran. He was delivering a keynote lecture on results of preliminary studies on Ramadan Fasting: the evidence and expert's opinion at the first scientific session of symposium of Ramadan and Health organized at Dow International Medical College DUHS Ojha Camps on October 26th 2013. This session was jointly chaired by Prof. Nighat Nisar, Prof. Nazeer Khan and Mr. Shaukat Ali Jawaid. Fasting, Dr. Mohsen Nematy said was not harmful for health. However, we need to study its health related effects in different regions due to variation in temperature. Furthermore there are different food habits in different regions, change in sleep pattern also have its effects. Hence the effects of fasting in patients suffering from coronary heart diseases, epilepsy, kidney diseases, IHD, Fatty Liver and many other disorders needs to be investigated in detail. Prof. Yakoob Ahmedani from Baqai Institute of Diabetes and Endocrinology (BIDE) made a presentation on Ramadan and Diabetes. He pointed out that over fifty million Muslims all over the world fast. Some time ago investigators from thirteen Muslim countries got together to discuss the risks and complications of fasting and came to the conclusion that it is safe for patients with diabetes to fast, both type one and type two but drug dosage needs to be altered. This EPIDIAR study showed that 64% of patients did not change their insulin dosage during fasting and no acute diabetic complication was observed during Ramadan.
Australia: Arena Pharmaceuticals Owns Trademark for 'BELVIQ' and 'WAVY STRIPE BREAKS DIAMOND'
Australia, Nov.26 -- Arena Pharmaceuticals GmbH, Switzerland, owns the trademark (1571921) for 'BELVIQ' and 'WAVY STRIPE BREAKS DIAMOND' from June 12, 2013, through June 12, 2023.
Eisai and BusinessOne Technologies announced that Eisai Inc. is using the Maestro Market Access Mobile™ application to educate physicians about detailed coverage levels for Eisai's recently approved BELVIQ(®) (lorcaserin HCI) CIV.
Market Access Mobile enables fact-based decisions and targeted strategies to increase clinical adoption and expand patient access. Eisai field representatives can produce detailed, drug-specific materials that educate physicians about product-specific access and patient out-of-pocket costs by health plan in the physician's area. With the information, physicians can navigate coverage for the drug, by plan, to enable prescribing for their patients.
"Market Access Mobile allows our field representatives to go in to physician's offices with current coverage data for various plans, to ensure patients have access to our medications, which is essential information for our product launch efforts," said Michael O'Brien, vice president, Specialty Marketing and Sales Business Unit at Eisai Inc. "With this information, providers will have a better understanding of plan-specific coverage details for BELVIQ."
Representatives, which spend most of their time out in the field, have anywhere, anytime access to Market Access Mobile. The mobile application allows representatives to access detailed obesity coverage policy information on more than 90 percent of the nation's covered lives. Where BELVIQ is covered, representatives will be able to create print-ready educational materials on the fly using a simple, three-step process.
First the AHA Guideline for the Management of Obesity comes out early in the week. Page 18 is the treatment algorithm in the form of a flow diagram. The first boxes in diagram are all about assessment. The first treatment box is lifestyle intervention alone or with adjunctive therapies. In case the physician does not get it, the next box spells out pharmacotherapy.
Then today JAMA posts the article entitled Long-term Drug Therapy for Obesity. The article starts off by pointing out that 36% of US adults are obese and many cannot lose sufficient weight to improve health with lifestyle intervention alone. The article goes on to provide an overview of weight management drugs available unequivocally stating that they provide additional options for weight management.
These publications represent a sea change from the thinking that diet and exercise are sufficient to combat the obesity epidemic. Physicians are being strongly encouraged (and given cover) to consider pharmacological options for overweight patients.
Eisai's job just got easier. When their reps go visiting physicians, they will be well-armed with guidelines from very respected medical entities. Of course there will be those "deniers" out there within the medical community, but that crowd will gradually dissipate. And physicians will not be starting out with the bariatric surgery treatment option. Hmmm, I wonder which pharmaceutical they will prescribe first to their overweight patients.
Jack said that in the context of why they chose Eisai for ROW. Reading between the lines, I took it to mean that the other interested suitors were not willing to share the costs of trials/regulatory applications for other potential uses for lorcaserin. Other suitors would have been willing to market Belviq in ROW, but not eager to pay costs of trials for unproven applications. Eisai on the other hand has been talking to physicians prescribing lorcaserin and didn't hesitate to ante up for smoking cessation trials, Belphen trials, time-release Belviq trials, etc. I like the decision as I think Eisai now has maximum incentive to make Eisai a success here in the US, now knowing that they will also be the beneficiary of spillover benefits overseas.
Sweet. Almost looks like an endorsement coming right after the Medical Options page. Hope this gets wide circulation. Thanks to you too hotmeel.
The planned expansion of the sales force follows increased coverage of BELVIQ by payors since the treatment first became available. According to BusinessOne Technologies, a leader in managed markets-focused integrated data and analytics business solutions, in addition to existing coverage, BELVIQ is now also covered by several prominent health plans and pharmacy benefit managers (PBMs) including, but not limited to, Express Scripts (including its legacy Express Scripts and Medco operations), Tufts, Health Alliance Plan, Excellus BCBS, Highmark BCBS, BCBS of Michigan, BCBS of North Carolina, and Healthnet (California). While the exact coverage for BELVIQ varies by patient, this improved access means more patients will receive coverage support from their health plan or PBM. Patients can determine their precise benefit by calling their healthcare plan provider or PBM.
"Eisai is deeply committed to launching innovative therapies with strong support by the payor community. The expansion of our sales force demonstrates the success we have gained in discussing the potential value of BELVIQ in chronic weight management within the payor community, and the subsequent agreements we have reached with many of our payor partners," said Lonnel Coats, President and Chief Executive Officer, Eisai Inc. "We are in very active and productive discussions with other major payors and fully expect the reimbursement landscape will further improve as we head into 2014."
"Eisai launched BELVIQ with a focus on educating an initial group of physicians, expanding reimbursement coverage, introducing patient support programs and increasing patient awareness," said Jack Lief, Arena's President and Chief Executive Officer. "We have seen increasing physician interest in BELVIQ as an important treatment option for chronic weight management, the payor landscape has improved and we are encouraged by the early response to the patient support programs and recently launched patient campaign. Eisai's efforts have led to month over month increases in BELVIQ prescriptions to date, and we expect that the expansion of the BELVIQ sales force will help communicate the safety and efficacy of BELVIQ to an increased number of physicians."
Lonnel Coats, Eisai Inc.'s President and Chief Executive Officer, added, "Eisai is deeply committed to launching innovative therapies with strong support from the payor community. The expansion of our sales force demonstrates the success we have gained in discussing the potential value of BELVIQ in chronic weight management within the payor community, and the subsequent agreements we have reached with many of our payor partners. We are in very active and productive discussions with other major payors and fully expect the reimbursement landscape will further improve as we head into 2014."
Thanks Sharon. Nice list of publications for coming ads.
Thanks once again Sharon (false). And gracias to artichoke heart for posting the link to picture below.